ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

174
Analysis
Health Care • South Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
•23 Oct 2020 13:14

Will SK Holdings Required to Sell a 25% Stake in SK Biopharm Due to Changes in the Fair Trade Act?

One of the most important developments arising in Korea is the potential amendment of the Fair Trade Act, which includes taking strict actions...

Logo
484 Views
Share
•01 Jul 2020 06:11

Korea Stock Market Monthly Recap #49 (June 2020)

Review of Top 10 Issues Related to Korean stock market, economy, & politics in June 2020: SK Biopharm IPO SK Holdings downgrade Capital gains...

Logo
532 Views
Share
•01 Jun 2020 08:10

Korea Stock Market Monthly Recap #48 (May 2020)

Review of Top 10 Issues Related to Korean stock market, economy, & politics in May 2020 Big interest in SK Biopharm IPO Announcements of IPOs...

Logo
518 Views
Share
bearish•SKC Co Ltd
•27 Feb 2026 06:01

SKC: Rights Offering of 1 Trillion Won

We believe that the market is likely to view the 1 trillion won rights offering of SKC negatively mainly due to 23.6% share dilution and worsening...

Logo
352 Views
Share
bullish•HK inno.N
•18 Feb 2026 08:30

HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card

​HK inno.N reports strong 4Q25 results, driven by prescription drug sales. The company has filed NDA for K-CAB in the U.S. and expects to launch...

Logo
248 Views
Share
x